ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
| Autor: | David Sibon, Bettina Bisig, Christophe Bonnet, Elsa Poullot, Emmanuel Bachy, Doriane Cavalieri, Virginie Fataccioli, Cloe Bregnard, Fanny Drieux, Julie Bruneau, Francois Lemonnier, Aurelie Dupuy, Celine Bossard, Marie Parrens, Krimo Bouabdallah, Nicolas Ketterer, Gregoire Berthod, Anne Cairoli, Gandhi Damaj, Olivier Tournilhac, Jean-Philippe Jais, Philippe Gaulard, Laurence de Leval |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Haematologica, Vol 108, Iss 6 (2022) |
| Druh dokumentu: | article |
| ISSN: | 0390-6078 1592-8721 |
| DOI: | 10.3324/haematol.2022.281442 |
| Popis: | ALK-negative anaplastic large cell lymphoma (ALCL) comprises subgroups harboring rearrangements of DUSP22 (DUSP22- R) or TP63 (TP63-R). Two studies reported 90% and 40% 5-year overall survival (OS) rates in 21 and 12 DUSP22-R/TP63- not rearranged (NR) patients, respectively, making the prognostic impact of DUSP22-R unclear. Here, 104 newly diagnosed ALK-negative ALCL patients (including 37 from first-line clinical trials) from the LYSA TENOMIC database were analyzed by break-apart fluorescence in situ hybridization assays for DUSP22-R and TP63-R. There were 47/104 (45%) DUSP22-R and 2/93 (2%) TP63-R cases, including one DUSP22-R/TP63-R case. DUSP22-R tumors more frequently showed CD3 expression (62% vs. 35%, P=0.01), and less commonly a cytotoxic phenotype (27% vs. 82%; P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|